Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
Anas Younes, SVP, CMO and Global Head of Hematology, Oncology R and D at AstraZeneca, shared on LinkedIn:
”Every year, ASH25 is a moment to recognize the progress we’re making in hematology and celebrate the breakthroughs that help to transform care, from next-generation T-cell engagers to advances in cell therapy.
At AstraZeneca, we’re advancing a diverse range of innovations and expanding access to next-generation therapies that aim to deliver deeper, more durable responses while easing the daily burden of treatment for people living with blood cancer.
It’s great to continue these conversations throughout ASH and explore how these breakthroughs are potentially shaping a more hopeful future for blood cancer care.
Read my latest article to learn more.”
All from ASH25 featured in Hemostasis Today.
-
Apr 23, 2026, 15:5810 Treating Fairly Research Awards – ASH
-
Apr 23, 2026, 15:51Abeer Alanazi: Secondary Stroke Prevention in Atrial Fibrillation
-
Apr 23, 2026, 15:46Brian O Mahony: What Causes the Battle Bettle Between AAV and the Liver?
-
Apr 23, 2026, 15:45Toong Youttananukorn: Excited to Share Our Poster at WFH 2026
-
Apr 23, 2026, 15:42Flora Peyvandi: Management of Antithrombotic Treatment in Atrial Fibrillation
-
Apr 23, 2026, 15:38William Aird: Do We Really Need MCH?
-
Apr 23, 2026, 15:35Andrea Baldini։ Aspirin Prophylaxis Is Effective But Still Off-Label In Some Countries
-
Apr 23, 2026, 14:52Anticoagulation Management and Outcomes in Patients with Cancer-Associated Small Venous Thromboembolism – JTH
-
Apr 23, 2026, 14:46Mital Jhaveri: Anticoagulant Approval and Uptake Timeline